If you have been reading about circadian clock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== Oxidation === Plasma processing, corona treatment, and flame treatment can all be classified as surface oxidation mechanisms. These methods all involve cleavage of polymer chains in the material and the incorporation of carbonyl, and hydroxyl functional groups. The incorporation of oxygen into the surface creates a higher surface energy allowing the substrate to be coated.
Kinohimitsu (木の秘密, Kinohimitsu) is a functional beauty and health brand owned by Kino Biotech, a leading integrated bio-nutraceutical and cosmeceutical public listed company in the Taiwan's GreTai Securities Market (GTSM) with its head office in Singapore. According to Euromonitor International, Kinohimitsu was the top selling beauty drink and collagen drink in Malaysia and Singapore between 2008 and 2010. The brand name, (木の秘密) means the secret of Nature.
Long-term use of benzodiazepines is associated with increased risk of cognitive impairment and dementia, and a reduction in prescribing levels is likely to reduce dementia risk. The association of a history of benzodiazepine use and cognitive decline is unclear, with some studies reporting a lower risk of cognitive decline in former users, some finding no association and some indicating an increased risk of cognitive decline. Benzodiazepines are sometimes prescribed to treat behavioral symptoms of dementia. However, like antidepressants, they have little evidence of effectiveness, although antipsychotics have shown some benefit. Cognitive impairing effects of benzodiazepines that occur frequently in the elderly can also worsen dementia.
Sources: en.wikipedia.org
=== Category:EC 3.1 (act on ester bonds) === Nuclease Endonuclease Exonuclease Category:EC 3.1.1 Acid hydrolase Phospholipase A (EC 3.1.1.4) Acetylcholinesterase (EC 3.1.1.7) Cholinesterase (EC 3.1.1.8) Lipoprotein lipase (EC 3.1.1.34) Category:EC 3.1.2 Ubiquitin carboxy-terminal hydrolase L1 (EC 3.1.2.15) Category:EC 3.1.3 Phosphatase Alkaline phosphatase (EC 3.1.3.1) Fructose bisphosphatase (EC 3.1.3.11) Category:EC 3.1.4 Phospholipase C (EC 3.1.4.3) CGMP specific phosphodiesterase type 5 (EC 3.1.4.17) Phospholipase D (EC 3.1.4.50) (3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring))-phosphatase Category:EC 3.1.21 Restriction enzyme Type 1 (EC 3.1.21.3) Restriction enzyme Type 2 (EC 3.1.21.4) Restriction enzyme Type 3 (EC 3.1.21.5) Restriction enzyme Type 4 (?) Deoxyribonuclease I (EC 3.1.21.1) Category:EC 3.1.26 RNase H (EC 3.1.26.4) Category:EC 3.1.27 Ribonuclease
Early in 1953 Watson and Crick proposed a correct structure for the DNA double helix. Pauling later cited several reasons to explain how he had been misled about the structure of DNA, among them misleading density data and the lack of high quality X-ray diffraction photographs. Pauling described this situation as "the biggest disappointment in his life". During the time Pauling was researching the problem, Rosalind Franklin in England was creating the world's best images. They were key to Watson's and Crick's success. Pauling did not see them before devising his mistaken DNA structure, although his assistant Robert Corey did see at least some of them, while taking Pauling's place at a summer 1952 protein conference in England. Pauling had been prevented from attending because his passport was withheld by the State Department on suspicion that he had Communist sympathies. This led to the legend that Pauling missed the structure of DNA because of the politics of the day (this was at the start of the McCarthy period in the United States). Politics did not play a critical role. Not only did Corey see the images at the time, but Pauling himself regained his passport within a few weeks and toured English laboratories well before writing his DNA paper. He had ample opportunity to visit Franklin's lab and see her work, but chose not to. Despite these times, Pauling chose to move on from them and be thankful for the discoveries that he had already found.
Historically, American black bears occupied the majority of North America's forested regions. Today, they are primarily limited to sparsely settled, forested areas. American black bears currently inhabit much of their original Canadian range, though they seldom occur in the southern farmlands of Alberta, Saskatchewan and Manitoba; they have been extirpated on Prince Edward Island since 1937. Surveys taken in the mid-1990s found the Canadian black bear population to be between 396,000 and 476,000 in seven provinces; this estimate excludes populations in New Brunswick, the Northwest Territories, Nova Scotia and Saskatchewan. All provinces indicated stable populations of American black bears over the 2000s. The current range in the United States is constant throughout most of the Northeast and within the Appalachian Mountains almost continuously from Maine to northern Georgia, the northern Midwest, the Rocky Mountain region, the West Coast and Alaska. However, it becomes increasingly fragmented or absent in other regions. Despite this, American black bears in those areas seem to have expanded their range in recent decades, such as with sightings in Ohio, Illinois, southern Indiana, and western Nebraska. Sightings of itinerant black bears in the Driftless Area of southeastern Minnesota, northeastern Iowa, and southwestern Wisconsin are common.
== Development == PMCA was originally developed to, in vitro, mimic prion replication with a similar efficiency to the in vivo process, but with accelerated kinetics. PMCA is conceptually analogous to the polymerase chain reaction - in both systems a template grows at the expense of a substrate in a cyclic reaction, combining growing and multiplication of the template units.
Sources: en.wikipedia.org
Catatonia associated with autism spectrum disorder Catatonia associated with schizophrenia spectrum and other psychotic disorders Catatonia associated with brief psychotic disorder Catatonia associated with schizophreniform disorder Catatonia associated with schizoaffective disorder Catatonia associated with a substance-induced psychotic disorder Catatonia associated with bipolar and related disorders Catatonia associated with major depressive disorder Catatonic disorder due to another medical condition If catatonic symptoms are present but do not form the catatonic syndrome, a medication- or substance-induced aetiology should be considered first.
== Before 1947 == "Indian", which has been used as an alternative for the Indigenous peoples of the Americas, originated with Christopher Columbus, who, in his search for India, thought that he had arrived in the East Indies. This historical misnomer has persisted over the centuries, shaping cultural perceptions and narratives surrounding Native American identity.
== Clinical studies == Arsenic trioxide was clinically tested in two open-label, single-arm trials without a control group, involving 52 patients with acute promyelocytic leukemia who had previously been unsuccessfully treated with anthracyclines and retinoids. The results of these studies are presented in the table below.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.